论文部分内容阅读
目的:观察依达拉奉联合丹参酮ⅡA治疗急性脑梗死的临床疗效。方法:130例急性脑梗死随机分为治疗组和对照组,治疗组在常规治疗的基础上给予依达拉奉30mg加生理盐水100ml静滴,2次/d,丹参酮ⅡA80mg加入生理盐水250ml静滴,1次/d;对照组给予川芎嗪160mg加入生理盐水250ml静滴,1次/d;2组均以14天为一疗程。于疗程结束时分别与治疗前进行神经功能缺损评分比较,并进行治疗后组间比较,同时进行2组间临床疗效对比。结果:疗程结束后治疗组与对照组神经功能缺损评分比较差异具有显著性(P<0.05),2组间临床疗效比较,治疗组总有效率显著高于对照组(P<0.05)。结论:依达拉奉联合丹参酮IIA治疗急性脑梗死疗效显著。
Objective: To observe the clinical efficacy of edaravone combined with tanshinone Ⅱ A in the treatment of acute cerebral infarction. Methods: 130 cases of acute cerebral infarction were randomly divided into treatment group and control group. The treatment group was given edaravone 30mg plus saline 100ml intravenously, twice a day, tanshinone Ⅱ A80mg added 250ml normal saline , 1 / d; control group given ligustrazine 160mg 250ml intravenous infusion of saline, 1 / d; 2 groups were 14 days for a course of treatment. At the end of the treatment, neurological deficit scores were compared with those before treatment. After treatment, the comparison between the two groups was made, and the clinical efficacy was compared between the two groups. Results: After treatment, the difference of neurological deficit score between the treatment group and the control group was significant (P <0.05). The clinical efficacy of the two groups was significantly higher than that of the control group (P <0.05). Conclusion: Edaravone combined with tanshinone IIA is effective in treating acute cerebral infarction.